Related Experiment Video
Updated: Jul 25, 2025

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
Published on: December 7, 2012
Effects of storage on quality and function of acid-treated platelets with reduced HLA Class I surface expression
Mohammad Reza Mirlashari1, Annette Vetlesen1, Lise Sofie H Nissen-Meyer1
1Department of Immunology and Transfusion Medicine, Oslo University Hospital, Oslo, Norway.
Background:
Refractory patients need to be provided with HLA-matched platelets (PLTs), which require time-consuming cross-matching. Treatment of PLTs with citric acid leads to denaturation of the HLA Class I complexes without significant damage to the PLTs. HLA Class I depleted PLTs could alternatively be used to HLA-matched PLTs for transfusion. These PLTs have verified normal function up to 4-6 h after acid treatment.
Materials And Methods:
Buffy coat (BC) PLT concentrates were depleted of HLA Class I complexes by incubation in citric acid. The days after acid-treatment, surface expression of HLA Class I complexes, CD62P and CD63 were determined by flow cytometry, in addition to viability and mitochondrial membrane potential (MMP). Thromboelastography (TEG) tested PLT functionality.
Results:
Expression of HLA Class I complexes was reduced by 70%-75% in acid-treated PLTs compared to untreated PLTs from day 1 through day 7. Controls and acid-treated PLTs showed insignificant loss of MMP stored for 4 days. Analysis of the residual PLT activation and viability showed no significant differences for 4 days of storage. However, the residual PLT activation potential and viability were significantly decreased in acid-treated PLTs and control PLTs after 7 days of storage. Acid treatment caused a significant decrease in the TEG variable, reaction time (R time), for acid-treated PLTs as compared to control PLTs from days 1 through day 3.
Conclusion:
Our data suggest that extended storage of acid-treated PLTs is possible and will improve flexibility when planning for transfusion of patients with alloimmune PLT refractoriness caused by anti-HLA-antibodies.
More Related Videos
10:32Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination
Published on: August 24, 2015
05:49Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
Published on: November 29, 2024